EFTA Document EFTA01820357

To: From: erey pis em Sent: Fri 10/23/2009 10:08:57 AM Subject: Re: FW: <no subject> send this Andrew- on an operating basis -yes- , However to recreate the network,and current "assets" would take 2-3 years, and more money than that. the businesses usually arc valued at one times revenue" most recent sales have been at a small multiple of that. I am aware of the potential, as are you. If you prefer , we can structure it as a convertible preferred. I look forward to hearing from you On Thu, Oct 22, 2009 at 11:36 PM, wrote: Forwarded Messa e From: Andrew Nikou Date: Thu, 22 Oct 20O9 08:00:35 -0700 To: Subject: RE: <no subject> the business is losing money. I don't see you us even close to an 8 million dollar valuation. Andrew Nikou Founder & Managing Partner OpenGate Capital, LLC 1999 Avenue of the Stars I Suite 1830 Los Angeles I CA 190067 +1 310 432 7000 I Office +1 310 868 2813 Fax US Mobile French Mobile A Save a tree. Please only print this e-mail if it is genuinely required. From: Sent: Wednesday, October 21, 2009 8:50 PM To: Andrew Nikou Subject: <no subject> Hi Andrew Thank you for coming to the office, it was a real pleasure to meet you. I don't really know what you have in your mind for the future of your modeling operation in America, but I am willing to sell 50% of the shares for the amount of US$ 4M. If you are still in NY, I would be very happy to meet you again. Best Regards PROT2 PROT0 End of Forwarded Message The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Jeffrey Epstein Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jccvacation@gmail.com, and destroy this communication and all copies thereof, including all attachments. PROT3 PROT1